Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -242.25% is 119% below its 5-year average of -110.74%, near the low end of its 5-year range (-242.25%–-23.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.45% below its 12-month average of -185.70%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -242.25%.
RETURN ON INVESTED CAPITAL (ROIC)
-242.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-185.70%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-153.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-110.74%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-81.06%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-30.45%
CURRENT VS 3Y AVG
-57.36%
CURRENT VS 5Y AVG
-118.75%
CURRENT VS 10Y AVG
-198.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
-579.34%
vs the sector median at left
Moleculin Biotech, Inc.
Market Cap
$2.38M
Return on Invested Capital (ROIC)
-242.25%
TTM Avg
-185.70%
3Y Avg
-153.95%
5Y Avg
-110.74%
Market Cap
$2.38M
Return on Invested Capital (ROIC)
-58.05%
TTM Avg
-445.82%
3Y Avg
-256.67%
5Y Avg
-256.67%
Market Cap
$2.37M
Return on Invested Capital (ROIC)
-59.84%
TTM Avg
-167.05%
3Y Avg
-109.85%
5Y Avg
-118.30%
Market Cap
$2.37M
Return on Invested Capital (ROIC)
-286.46%
TTM Avg
-159.21%
3Y Avg
-198.72%
5Y Avg
-198.72%
Market Cap
$2.32M
Return on Invested Capital (ROIC)
-71.90%
TTM Avg
-86.03%
3Y Avg
-72.74%
5Y Avg
-64.31%
Market Cap
$2.44M
Return on Invested Capital (ROIC)
-110.81%
TTM Avg
-123.52%
3Y Avg
-108.42%
5Y Avg
-102.13%
Market Cap
$2.54M
Return on Invested Capital (ROIC)
-237.93%
TTM Avg
-187.67%
3Y Avg
-136.08%
5Y Avg
-136.08%
Market Cap
$2.56M
Return on Invested Capital (ROIC)
-238.32%
TTM Avg
-241.12%
3Y Avg
-206.72%
5Y Avg
-167.10%
Market Cap
$2.14M
Return on Invested Capital (ROIC)
-182.30%
TTM Avg
-118.66%
3Y Avg
-275.59%
5Y Avg
-206.48%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | $2.38M | -242.25% | -185.70% | -153.95% | -110.74% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | -58.05% | -445.82% | -256.67% | -256.67% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | -59.84% | -167.05% | -109.85% | -118.30% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | -286.46% | -159.21% | -198.72% | -198.72% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -71.90% | -86.03% | -72.74% | -64.31% |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | -110.81% | -123.52% | -108.42% | -102.13% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -237.93% | -187.67% | -136.08% | -136.08% |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | -238.32% | -241.12% | -206.72% | -167.10% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | -182.30% | -118.66% | -275.59% | -206.48% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -985.20% | -494.63% | -376.51% | -304.92% |
ROIC
-242.3%
ROE
-261.7%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -242.25% |
| 2026-03-31 | -175.53% |
| 2025-12-31 | -162.90% |
| 2025-09-30 | -163.56% |
| 2025-06-30 | -184.25% |
| 2025-03-31 | -181.91% |
| 2024-12-31 | -230.33% |
| 2024-09-30 | -162.44% |
| 2024-06-30 | -139.84% |
| 2024-03-31 | -109.90% |
| 2023-12-31 | -94.36% |
| 2023-09-30 | -77.90% |
| 2023-06-30 | -76.17% |
| 2023-03-31 | -69.35% |
| 2022-12-31 | -58.25% |
| 2022-09-30 | -48.80% |
| 2022-06-30 | -38.39% |
| 2022-03-31 | -32.38% |
| 2021-12-31 | -28.51% |
| 2021-09-30 | -24.99% |
| 2021-06-30 | -23.56% |
| 2021-03-31 | -21.81% |
| 2020-12-31 | -75.61% |
| 2020-09-30 | -88.84% |
| 2020-06-30 | -70.25% |
| 2020-03-31 | -80.63% |
| 2019-12-31 | -80.50% |
| 2019-09-30 | -88.43% |
| 2019-06-30 | -67.97% |
| 2019-03-31 | -114.10% |
| 2018-12-31 | -95.65% |
| 2018-09-30 | -79.23% |
| 2018-06-30 | -69.63% |
| 2018-03-31 | -42.17% |
| 2017-12-31 | -50.10% |
| 2017-09-30 | -35.51% |
| 2017-06-30 | -29.32% |
| 2017-03-31 | -29.39% |
| 2016-12-31 | -26.98% |
